Search

Not yet recruiting. Checked 2026-10-03. Difficult-to-treat bacterial infections; non-IV matched phage routes. ChiCTR2500102677

Status unconfirmed. Checked 2026-10-03. Multidrug-resistant ICU pneumonia; indexed criteria and investigator contact available. ChiCTR2500104137

Not yet recruiting. Checked 2026-10-03. Drug-resistant infections; English record emphasizes UTI while Chinese is broader. ChiCTR2600124009

Ended. Checked 2026-10-03. 2023-507203-55-00 2022-503145-22-00

Not yet recruiting. Checked 2026-10-03. 2025-521533-85-00

Not yet recruiting. Checked 2026-10-03. Phase1b/2a IV engineered phage antimicrobial for susceptible P. aeruginosa in adults18–60 with cystic fibrosis. ISRCTN57413769

Not recruiting. Checked 2026-10-03. Topical gel twice daily84days; Osaka Metropolitan University Hospital; age>=12. jRCTs051230164

Completed. Checked 2026-10-03. To test safety and efficacy of Bacteriophage on Venous Leg Ulcers. A Prospective, Randomized Double-Blind Controlled Study of WPP-201 for the Safety and Efficacy of Treatment of Venous Leg Ulcers WPP-201 Inclu

Terminated. Checked 2026-10-03. This study hopes to demonstrate the potentials of a new form of therapy for childhood diarrhea, a major cause of morbidity and deaths in Bangladesh and other developing countries, and thus a priority for impr

Status unconfirmed. Checked 2026-10-03. The primary purpose of this experimental therapy is to treat, with the aid of bacteriophages, patients with non-healing postoperative wounds or bone, upper respiratory tract, genital or urinary tract

Ended. Checked 2026-10-04. The objective of PHAGOBURN is to assess tolerance and efficacy of local bacteriophage treatment of E. coli or P. aeruginosa wound infections in burned patients. Phase I/II Clinical Trial Randomized, Multicentric,

Conflicting status. Checked 2026-10-03. The primary objective of this study is to compare the efficacy of standard treatment associated with a topical anti-staphylococcal bacteriophage cocktail versus standard treatment plus placebo for dia

Completed. Checked 2026-10-03. This study will examine the safety of ascending doses of AB-SA01 when topically applied to intact skin of healthy adults. Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact Skin of

Completed. Checked 2026-10-03. Urinary tract infections are among the most prevalent microbial diseases and their financial burden on society is substantial. The use of bacteriophages against bacterial pathogens has gained over the last yea

Completed. Checked 2026-10-03. The PHAGE study is designed to determine if a commercial prebiotic product can change the composition of bacteria in the gut for improved intestinal health. A prebiotic is defined as an indigestible dietary co

Unavailable. Checked 2026-10-03. The purpose of the expanded access program is to allow physicians to provide treatment with investigational drug, AB-PA01, for patients with serious or immediately life-threatening Pseudomonas aeruginosa inf

Unavailable. Checked 2026-10-03. The purpose of the expanded access program is to allow physicians to provide treatment with investigational drug, AB-SA01, for patients with serious or immediately life-threatening Staphylococcus aureus infe

Conflicting status. Checked 2026-10-03. This study will evaluate the safety of oral administration of EcoActive to patients with inactive Crohn's disease and how it affects the levels of AIEC in stool. A Phase 1/2a Double-Blind, Randomized,

Completed. Checked 2026-10-03. Study LBx-1001 is a multi-center randomized, double-blind study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of LBP-EC01 in patients with indwelling urinary catheters, or

Terminated. Checked 2026-10-03. This is a phase I/II trial designed to evaluate bacteriophage therapy in patients with urinary tract infections. A Phase I/II Study of Bacteriophage Therapy to Evaluate Safety, Tolerability, and Efficacy of T